CY1110426T1 - Συνδυασμοι dmxaa και αλλων αντικαρκινικων ουσιων - Google Patents
Συνδυασμοι dmxaa και αλλων αντικαρκινικων ουσιωνInfo
- Publication number
- CY1110426T1 CY1110426T1 CY20081101516T CY081101516T CY1110426T1 CY 1110426 T1 CY1110426 T1 CY 1110426T1 CY 20081101516 T CY20081101516 T CY 20081101516T CY 081101516 T CY081101516 T CY 081101516T CY 1110426 T1 CY1110426 T1 CY 1110426T1
- Authority
- CY
- Cyprus
- Prior art keywords
- combinations
- dmxaa
- cancer
- cancer substances
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0121285.1A GB0121285D0 (en) | 2001-09-03 | 2001-09-03 | Anti-cancer combinations |
| EP02758562A EP1423105B9 (en) | 2001-09-03 | 2002-09-03 | Combinations of dmxaa and other anti-cancer agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1110426T1 true CY1110426T1 (el) | 2015-04-29 |
Family
ID=9921418
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20081101516T CY1110426T1 (el) | 2001-09-03 | 2008-12-31 | Συνδυασμοι dmxaa και αλλων αντικαρκινικων ουσιων |
Country Status (23)
| Country | Link |
|---|---|
| US (6) | US7863322B2 (enExample) |
| EP (3) | EP1423105B9 (enExample) |
| JP (3) | JP2005509599A (enExample) |
| CN (5) | CN100536840C (enExample) |
| AT (1) | ATE415963T1 (enExample) |
| AU (1) | AU2002324143B2 (enExample) |
| BR (1) | BR0212258A (enExample) |
| CA (1) | CA2458459A1 (enExample) |
| CY (1) | CY1110426T1 (enExample) |
| DE (1) | DE60230159D1 (enExample) |
| DK (1) | DK1423105T3 (enExample) |
| EA (3) | EA200801611A1 (enExample) |
| ES (1) | ES2321283T3 (enExample) |
| GB (1) | GB0121285D0 (enExample) |
| IL (1) | IL160178A0 (enExample) |
| IS (1) | IS7144A (enExample) |
| MX (1) | MXPA04002004A (enExample) |
| NO (1) | NO20040591L (enExample) |
| NZ (5) | NZ567456A (enExample) |
| PT (1) | PT1423105E (enExample) |
| SI (1) | SI1423105T1 (enExample) |
| WO (1) | WO2003020259A2 (enExample) |
| ZA (1) | ZA200401078B (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY164077A (en) | 1999-05-13 | 2017-11-30 | Pharma Mar Sa | Compositions and uses of et743 for treating cancer |
| EP1189611B1 (en) * | 1999-06-14 | 2006-05-03 | Cancer Research Technology Limited | Cancer therapy |
| MXPA02011319A (es) | 2000-05-15 | 2003-06-06 | Pharma Mar Sa | Analogos antitumorales de ecteinascidina 743. |
| WO2002009700A1 (en) | 2000-07-28 | 2002-02-07 | Cancer Research Technology Limited | Cancer treatment by combination therapy |
| GB0121285D0 (en) | 2001-09-03 | 2001-10-24 | Cancer Res Ventures Ltd | Anti-cancer combinations |
| GB0202544D0 (en) | 2002-02-04 | 2002-03-20 | Pharma Mar Sa | The synthesis of naturally occuring ecteinascidins and related compounds |
| GB2386836B (en) | 2002-03-22 | 2006-07-26 | Cancer Res Ventures Ltd | Anti-cancer combinations |
| GB2394658A (en) | 2002-11-01 | 2004-05-05 | Cancer Rec Tech Ltd | Oral anti-cancer composition |
| GB0321999D0 (en) * | 2003-09-19 | 2003-10-22 | Cancer Rec Tech Ltd | Anti-cancer combinations |
| SI1689404T1 (sl) | 2003-11-13 | 2009-02-28 | Pharma Mar Sau | Kombinacija et-743 s 5-fluorouracil pro zdravili za zdravljenje raka |
| KR101188691B1 (ko) | 2004-10-29 | 2012-10-09 | 파르마 마르 에스.에이. | 엑티나시딘 및 디사카라이드를 포함하는 제제 |
| GB0517387D0 (en) * | 2005-08-26 | 2005-10-05 | Antisoma Res Ltd | Combinations for the treatment of cancer |
| CA2620436A1 (en) * | 2005-08-26 | 2007-03-01 | Antisoma Plc | Combinations comprising dmxaa for the treatment of cancer |
| GB0522082D0 (en) | 2005-10-31 | 2005-12-07 | Pharma Mar Sa | Formulations |
| GB0625283D0 (en) * | 2006-12-19 | 2007-01-24 | Cyclacel Ltd | Combination |
| CN101896177A (zh) * | 2007-12-13 | 2010-11-24 | 诺瓦提斯公司 | 用于治疗癌症的治疗剂的组合 |
| CN101279967B (zh) * | 2008-05-29 | 2010-11-10 | 武汉远大制药集团有限公司 | 一种治疗癌症的三甲基呫吨酮-4-乙酸药物组合物及其用途 |
| ES2545609T3 (es) | 2008-08-25 | 2015-09-14 | Amplimmune, Inc. | Composiciones de antagonistas de PD-1 y métodos de uso |
| US20100068302A1 (en) * | 2008-09-17 | 2010-03-18 | Traslational Cancer Drugs Pharma, S.L. | Methods and compositions for the treatment of cancer |
| WO2011019782A1 (en) * | 2009-08-11 | 2011-02-17 | Novartis Ag | Combinations of vascular disrupting agents with inhibitor of apoptosis proteins antagonists |
| DK3012329T3 (da) | 2010-06-18 | 2017-11-20 | Myriad Genetics Inc | Fremgangsmåder og materialer til at vurdere tab af heterozygositet |
| DK2609216T3 (en) | 2010-08-24 | 2016-09-12 | Dana Farber Cancer Inst Inc | Methods to predict anti-cancer response |
| CN102786509B (zh) * | 2011-05-16 | 2016-06-01 | 杭州民生药业有限公司 | 2-(5,6-二甲基呫吨酮-4-基)-乙酸的衍生物及其制备方法和用途 |
| EP3693473B1 (en) | 2011-06-17 | 2025-02-19 | Myriad Genetics, Inc. | Methods and materials for assessing allelic imbalance |
| BR112014015152A2 (pt) | 2011-12-21 | 2017-07-04 | Myriad Genetics Inc | métodos e materiais para a avaliação da perda de heterozigosidade |
| EP2617421A1 (en) * | 2012-01-20 | 2013-07-24 | Isofol Medical AB | Tetrahydrofolates in combination with EGFR-inhibitors in the use of treating cancer |
| DK3415915T3 (da) | 2012-02-23 | 2024-11-04 | Childrens Medical Center | Fremgangsmåde til at forudsige respons til PARP-inhibitorer |
| AU2013273466B2 (en) | 2012-06-07 | 2018-11-01 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods for detecting inactivation of the homologous recombination pathway (BRCA1/2) in human tumors |
| WO2014160080A1 (en) | 2013-03-14 | 2014-10-02 | Children's Medical Center Corporation | Cancer diagnosis, treatment selection and treatment |
| DK2981624T3 (da) | 2013-04-05 | 2020-03-02 | Myriad Genetics Inc | Fremgangsmåder til vurdering af homolog rekombinationsdeficiens og forudsigelse af respons på cancerbehandling |
| WO2014169067A1 (en) * | 2013-04-09 | 2014-10-16 | Merrimack Pharmaceuticals, Inc. | Compositions for improving outcomes of liposomal chemotherapy |
| EP3071209A4 (en) * | 2013-11-19 | 2017-08-16 | The University of Chicago | Use of sting agonist as cancer treatment |
| WO2015086473A1 (en) | 2013-12-09 | 2015-06-18 | Institut Curie | Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors |
| ES2946251T3 (es) | 2014-08-15 | 2023-07-14 | Myriad Genetics Inc | Métodos y materiales para evaluar la deficiencia de recombinación homóloga |
| EP4141127B1 (en) | 2021-08-30 | 2024-10-09 | Zentrum Familiärer Brust- und Eierstockkrebs Universitätsklinik Köln | Method for assessing homologous recombination deficiency in ovarian cancer cells |
| CN115282140B (zh) * | 2022-02-07 | 2024-03-08 | 南京市儿童医院 | Aki治疗剂及dmxaa在制备该治疗剂中的应用 |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2015265A1 (de) | 1969-03-29 | 1970-10-08 | Yoshitomi Pharmaceutical Industries Ltd., Osaka (Japan) | Arylalkansäuren und Verfahren zu deren Herstellung |
| US3655470A (en) | 1969-03-29 | 1972-04-11 | Toa Gosei Chem Ind | Process for the production of a foamed thermoplastic resin sheet |
| US4565806A (en) * | 1981-08-18 | 1986-01-21 | Setaelae Kai M E | Composition and method for rational treatment of cancer |
| FR2516922A1 (fr) | 1981-11-25 | 1983-05-27 | Lipha | Acides (oxo-4-4h-(1)-benzopyran-8-yl) alcanoiques, sels et derives, preparation et medicament les contenant |
| DE3587500T2 (de) * | 1984-12-04 | 1993-12-16 | Lilly Co Eli | Tumorbehandlung bei Säugetieren. |
| US4704355A (en) | 1985-03-27 | 1987-11-03 | New Horizons Diagnostics Corporation | Assay utilizing ATP encapsulated within liposome particles |
| US5281620A (en) | 1986-12-23 | 1994-01-25 | Cancer Research Campaign Technology Limited | Compounds having antitumor and antibacterial properties |
| JP2672101B2 (ja) | 1986-12-23 | 1997-11-05 | ディーエフシー ニュージーランド リミテッド | キサンテノン−４−酢酸誘導体 |
| JPH01193227A (ja) | 1988-01-29 | 1989-08-03 | Res Dev Corp Of Japan | 癌免疫療法補助剤 |
| US5126129A (en) | 1988-05-23 | 1992-06-30 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services | Cancer therapy using interleukin-2 and flavone compounds |
| US5075287A (en) | 1989-03-03 | 1991-12-24 | Nisshin Oil Mills, Inc. | Muramyl peptide derivatives and immunoregulating compositions containing them |
| CA2025907A1 (en) | 1989-09-21 | 1991-03-22 | Franklin D. Collins | Method of transporting compositions across the blood brain barrier |
| US5250296A (en) | 1990-11-29 | 1993-10-05 | Takeda Chemical Industries, Ltd. | Immunostimulant agent containing interleukin-2 and 5'-deoxy-5-fluorouridine |
| EP0551200A1 (en) | 1992-01-07 | 1993-07-14 | National University Of Singapore | Protein phosphatase inhibitors for use in therapy |
| CA2086874E (en) | 1992-08-03 | 2000-01-04 | Renzo Mauro Canetta | Methods for administration of taxol |
| GB9308166D0 (en) * | 1993-04-20 | 1993-06-02 | Cancer Res Campaign Tech | Cancer therapy |
| GB9320484D0 (en) | 1993-10-05 | 1993-11-24 | Wellcome Found | Pharmaceutical combinations |
| DE4417742A1 (de) * | 1994-05-20 | 1995-11-23 | Bayer Ag | Nicht-systemische Bekämpfung von Parasiten |
| US5620875A (en) | 1995-02-17 | 1997-04-15 | University Of Portland | Transfer of taxol from yew tree cuttings into a culture medium over time |
| AU5688596A (en) | 1995-04-13 | 1996-10-30 | Deutsche Om Arzneimittel Gmbh | Anti-cd14 antibodies for use in the induction of il-10 secre tion |
| AU5857296A (en) | 1995-05-17 | 1996-11-29 | Eli Lilly And Company | Use of leukotriene antagonists for alzheimer's disease |
| JPH0940690A (ja) | 1995-05-23 | 1997-02-10 | Yutaka Sashita | ステロイド配糖体及びこれを有効成分とする医薬 |
| WO1997004761A1 (en) | 1995-07-28 | 1997-02-13 | Trustees Of Boston University | Methods and compositions for treating cell proliferative disorders |
| US5977077A (en) | 1995-08-28 | 1999-11-02 | Interlab Corporation | Xanthone analogs for the treatment of infectious diseases |
| US5863904A (en) | 1995-09-26 | 1999-01-26 | The University Of Michigan | Methods for treating cancers and restenosis with P21 |
| JP2001509143A (ja) | 1996-12-13 | 2001-07-10 | イーライ・リリー・アンド・カンパニー | 大脳病巣性卒中のためのロイコトリエンアンタゴニスト |
| WO1998025600A1 (en) | 1996-12-13 | 1998-06-18 | Eli Lilly And Company | Leukotriene antagonists for treatment or inhibition of gout |
| UA47505C2 (uk) | 1996-12-13 | 2002-07-15 | Елі Ліллі Енд Компані | Спосіб лікування плоскоклітинного раку ротової порожнини за допомогою антагоністів лейкотриєну |
| ATE241993T1 (de) | 1997-03-11 | 2003-06-15 | Aeterna Lab Inc | Zubereitungen zur tumorbehandlung enthaltend hai- knorpelextrakte und antineoplastische mittel |
| US5998454A (en) | 1997-03-21 | 1999-12-07 | Eli Lilly And Company | Leukotriene antagonists useful for treating iritis |
| US5914340A (en) | 1997-03-21 | 1999-06-22 | Eli Lilly And Company | Leukotriene antagonists useful for treating dermatoses |
| AU6570798A (en) | 1997-03-21 | 1998-10-20 | Eli Lilly And Company | Leukotriene antagonists useful for treating gingivitis |
| AU6572298A (en) | 1997-03-21 | 1998-10-20 | Eli Lilly And Company | Leukotriene antagonists useful for treating ischemia reperfusion injury |
| US5910505A (en) | 1997-03-21 | 1999-06-08 | Eli Lilly And Company | Leukotriene antagonists for use in the treatment or inhibition of oral squamous cell carcinoma |
| WO1998042650A2 (en) | 1997-03-21 | 1998-10-01 | Eli Lilly And Company | Leukotriene antagonists useful for treating cystic fibrosis |
| AU6450498A (en) | 1997-03-21 | 1998-10-20 | Eli Lilly And Company | Leukotriene antagonists useful for treating gout |
| WO1998042345A1 (en) | 1997-03-21 | 1998-10-01 | Eli Lilly And Company | Leukotriene antagonists useful for treating cerebral focal stroke |
| DE19721211A1 (de) | 1997-05-21 | 1998-11-26 | Lindner Sen Wolfgang Dr Med | Kombination von antientzündlichen Wirkstoffen mit immunstimulierenden Agentien und zytotoxischen Agentien zur Behandlung von Tumoren |
| JP2002523378A (ja) | 1998-08-24 | 2002-07-30 | マキシム ファーマシューティカルズ インコーポレイテッド | Ｈ２−レセプターアゴニストおよび他のｔ−細胞活性化薬剤を用いたｔ−細胞（ｃｄ４＋およびｃｄ８＋）の活性化および保護 |
| AU757649B2 (en) | 1998-09-10 | 2003-02-27 | Genaera Corporation | Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities |
| AUPP609198A0 (en) | 1998-09-22 | 1998-10-15 | Curtin University Of Technology | Use of non-peptidyl compounds for the treatment of insulin related ailments |
| US6174873B1 (en) | 1998-11-04 | 2001-01-16 | Supergen, Inc. | Oral administration of adenosine analogs |
| GB9903404D0 (en) | 1999-02-16 | 1999-04-07 | Angiogene Pharm Ltd | Methods of treatment and compositions useful for the treatment of diseases involving angiogenesis |
| EP1033364B1 (en) | 1999-03-01 | 2005-02-23 | Pfizer Products Inc. | Cyano containing oxamic acids and derivatives as thyroid receptor ligands |
| EP1189611B1 (en) | 1999-06-14 | 2006-05-03 | Cancer Research Technology Limited | Cancer therapy |
| US6806257B1 (en) | 1999-10-20 | 2004-10-19 | Board Of Trustees Of Southern Illinois University | Flavones as inducible nitric oxide synthase inhibitors, cyclooxygenase-2 inhibitors and potassium channel activators |
| WO2001034198A2 (en) | 1999-11-11 | 2001-05-17 | Eli Lilly And Company | Oncolytic combinations for the treatment of cancer |
| WO2001034135A2 (en) | 1999-11-11 | 2001-05-17 | Eli Lilly And Company | Oncolytic combinations for the treatment of cancer |
| AU1916501A (en) | 1999-11-11 | 2001-06-06 | Eli Lilly And Company | Oncolytic combinations for the treatment of cancer |
| CZ20021551A3 (cs) | 1999-11-11 | 2003-02-12 | Eli Lilly And Company | Onkolytické kombinace pro léčení rakoviny |
| AU3822701A (en) | 2000-02-17 | 2001-08-27 | Merck & Co., Inc. | Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug |
| JP2001247459A (ja) * | 2000-03-03 | 2001-09-11 | Oakland Uniservices Ltd | 癌の組み合わせ療法 |
| WO2002009700A1 (en) * | 2000-07-28 | 2002-02-07 | Cancer Research Technology Limited | Cancer treatment by combination therapy |
| GB0121285D0 (en) | 2001-09-03 | 2001-10-24 | Cancer Res Ventures Ltd | Anti-cancer combinations |
| GB2386836B (en) | 2002-03-22 | 2006-07-26 | Cancer Res Ventures Ltd | Anti-cancer combinations |
| GB2394658A (en) | 2002-11-01 | 2004-05-05 | Cancer Rec Tech Ltd | Oral anti-cancer composition |
| GB0321999D0 (en) | 2003-09-19 | 2003-10-22 | Cancer Rec Tech Ltd | Anti-cancer combinations |
| GT200500186A (es) * | 2004-07-07 | 2006-03-02 | Regimenes anticonceptivos con antagonistas del receptor de progesterona y kits | |
| GB0517387D0 (en) | 2005-08-26 | 2005-10-05 | Antisoma Res Ltd | Combinations for the treatment of cancer |
| CA2620436A1 (en) | 2005-08-26 | 2007-03-01 | Antisoma Plc | Combinations comprising dmxaa for the treatment of cancer |
| BRPI0817712A2 (pt) | 2007-10-23 | 2015-03-31 | Antisoma Res Ltd | Sal de sódio cristalino de ácido 5,6-dimetil-oxo-xantano-4-acético, forma cristalina do mesmo, processos para preparar sal de sódio cristalino de ácido 5,6-dimetil-oxo-xantano-4-acético, e, para preparar forma cristalina, composição farmacêutica, método para preparar uma composição farmacêutica, uso de um sal de sódio cristalino de dmxaa, método para tratar câncer, kit de partes, e, formulação farmacêutica |
-
2001
- 2001-09-03 GB GBGB0121285.1A patent/GB0121285D0/en not_active Ceased
-
2002
- 2002-09-03 BR BR0212258-8A patent/BR0212258A/pt not_active IP Right Cessation
- 2002-09-03 MX MXPA04002004A patent/MXPA04002004A/es active IP Right Grant
- 2002-09-03 ES ES02758562T patent/ES2321283T3/es not_active Expired - Lifetime
- 2002-09-03 NZ NZ567456A patent/NZ567456A/en not_active IP Right Cessation
- 2002-09-03 EA EA200801611A patent/EA200801611A1/ru unknown
- 2002-09-03 AU AU2002324143A patent/AU2002324143B2/en not_active Ceased
- 2002-09-03 NZ NZ546573A patent/NZ546573A/en not_active IP Right Cessation
- 2002-09-03 DK DK02758562T patent/DK1423105T3/da active
- 2002-09-03 EA EA200400370A patent/EA008056B1/ru not_active IP Right Cessation
- 2002-09-03 DE DE60230159T patent/DE60230159D1/de not_active Expired - Lifetime
- 2002-09-03 CA CA002458459A patent/CA2458459A1/en not_active Abandoned
- 2002-09-03 CN CNB028172574A patent/CN100536840C/zh not_active Expired - Fee Related
- 2002-09-03 NZ NZ576925A patent/NZ576925A/en not_active IP Right Cessation
- 2002-09-03 CN CNA2009101604101A patent/CN101596187A/zh active Pending
- 2002-09-03 NZ NZ554093A patent/NZ554093A/en not_active IP Right Cessation
- 2002-09-03 CN CNA2006101513931A patent/CN1994287A/zh active Pending
- 2002-09-03 EA EA200601118A patent/EA010857B1/ru not_active IP Right Cessation
- 2002-09-03 AT AT02758562T patent/ATE415963T1/de active
- 2002-09-03 EP EP02758562A patent/EP1423105B9/en not_active Expired - Lifetime
- 2002-09-03 PT PT02758562T patent/PT1423105E/pt unknown
- 2002-09-03 JP JP2003524567A patent/JP2005509599A/ja not_active Ceased
- 2002-09-03 IL IL16017802A patent/IL160178A0/xx unknown
- 2002-09-03 EP EP06077049A patent/EP1759694A3/en not_active Withdrawn
- 2002-09-03 WO PCT/GB2002/004025 patent/WO2003020259A2/en not_active Ceased
- 2002-09-03 NZ NZ531045A patent/NZ531045A/en not_active IP Right Cessation
- 2002-09-03 CN CNA2009101604099A patent/CN101596186A/zh active Pending
- 2002-09-03 SI SI200230798T patent/SI1423105T1/sl unknown
- 2002-09-03 CN CNA2009101604084A patent/CN101607087A/zh active Pending
- 2002-09-03 EP EP10001750A patent/EP2236134A1/en not_active Withdrawn
-
2004
- 2004-02-06 IS IS7144A patent/IS7144A/is unknown
- 2004-02-10 ZA ZA200401078A patent/ZA200401078B/en unknown
- 2004-02-10 NO NO20040591A patent/NO20040591L/no unknown
- 2004-03-02 US US10/790,943 patent/US7863322B2/en not_active Expired - Fee Related
-
2006
- 2006-11-03 US US11/592,678 patent/US20070060637A1/en not_active Abandoned
-
2007
- 2007-07-30 US US11/830,659 patent/US7868040B2/en not_active Expired - Fee Related
- 2007-07-30 US US11/830,677 patent/US7863321B2/en not_active Expired - Fee Related
- 2007-07-30 US US11/830,668 patent/US7863320B2/en not_active Expired - Fee Related
- 2007-07-30 US US11/830,650 patent/US7868039B2/en not_active Expired - Fee Related
-
2008
- 2008-12-31 CY CY20081101516T patent/CY1110426T1/el unknown
-
2009
- 2009-06-03 JP JP2009133903A patent/JP2009263371A/ja active Pending
-
2010
- 2010-07-01 JP JP2010151115A patent/JP2010270124A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IS7144A (is) | Lyfjablöndur gegn krabbameini | |
| BR9807824A (pt) | Derivados de n-hidróxi-beta-sulfonil-propionamida e seu uso como inibidores de metaloproteinases de matriz | |
| ES2145774T3 (es) | Derivados de adenosina que tienen actividad agonista en a2. | |
| AR023423A1 (es) | Derivados de adamantano, procedimientos para su preparacion, composicion farmaceutica, procedimiento para la preparacion de la composicion farmaceutica, yuso de dichos derivados para la manufactura de medicamentos | |
| CY1118206T1 (el) | Φαρμακευτικη συνθεση για δερματικη χρηση για να θεραπευεται ψωριαση που περιλαμβανει καλσιποτριολη και βηταμεθαζονη | |
| IS6491A (is) | Pteridínefnasambönd til meðhöndlunar á sóríasis | |
| BRPI0007487B8 (pt) | difenil-uréias substituídas com w-carbóxi-arilas como inibidores de raf cinase | |
| SE0301700D0 (sv) | Novel compounds | |
| UY27943A1 (es) | Composiciones y mctodos para tratar el crncer usando inmunoconjugados de anticuerpo para cd44 citotnxicos y agentes quimioterapcuticos | |
| AR021844A1 (es) | Derivados de propanolamina aril-sustituidos, procedimientos para su preparacion, medicamentos que contienen estos compuestos y su utilizacion | |
| TR200101969T2 (tr) | Enflamasyon tedavisi için sübstitüe edilmiş benzopiran analogları. | |
| ES2056190T3 (es) | Derivados de 4(4-fenil-1-piperazinil)fenoles, inhibidores de 5-lipoxigenasa. | |
| GT200500007A (es) | [1,8]naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia. | |
| AR030185A1 (es) | Glutarimidas sustituidas, su preparacion, medicamentos que las contienen, y uso de las mismas para la fabricacion de medicamentos, especialmente inmunomoduladores, como asi tambien inhibidores de angiopatias y/o enfermedades hematologicas/oncologicas | |
| EP1028758A4 (en) | METHOD FOR TREATING PROSTATE TUMORS WITH RADIOACTIVE COMPOSITIONS | |
| SE9802729D0 (sv) | Novel Compounds | |
| ECSP045520A (es) | Metodos de tratamiento con inhibidores de la ptec y agentes antihipertensivos | |
| BG101290A (en) | New promedicaments for the therapy of tumours and inflammatory diseases | |
| ES2136037B1 (es) | Inhibidores de sulfamida-metaloproteasa | |
| BR9916004A (pt) | Inibidores de proteinase c de pró-colágeno | |
| DK1063995T3 (da) | Kombination til behandling af alkoholafhængighed indeholdende en opiod-antagonist og en NMDA-receptorkompleks-modulator | |
| HRPK20030734B3 (en) | A combination comprising combretastatin and anticancer agents | |
| ATE240303T1 (de) | 1,2,4-triazol-3-thion verbindungen | |
| NO995685D0 (no) | Nye glycosylerte ginkgolidderivater, anvendelse derav som medikamenter og farmasöytiske blandinger | |
| ATE225179T1 (de) | Synergistische zusammensetzung zur behandlung von krebs, welche inulin und ein antikrebsmittel enthält |